People · Operator

Ting G. Xiao

Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology

1
Companies
1
Filings
$58.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
OncoMyx Therapeutics, Inc.BiotechnologySeries C$58.0M$1.2B2019
Operator network

Ting G. Xiao at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Benjamin J. Rovinski, Ph.D. · 1 companies · 1 sharedBenjamin J. Rovin…Charles M. Baum, M.D., Ph.D. · 1 companies · 1 sharedCharles M. Baum, …Douglas Grant McFadden, Ph.D. · 1 companies · 1 sharedDouglas Grant McF…Jason G. Rushton · 1 companies · 1 sharedJason G. RushtonKanad G. Das, Ph.D. · 1 companies · 1 sharedKanad G. Das, Ph.…Kanad J. Das, Ph.D. · 1 companies · 1 sharedKanad J. Das, Ph.…Leslie M. Sharp, Ph.D. · 1 companies · 1 sharedLeslie M. Sharp, …Michael G. Wood · 1 companies · 1 sharedMichael G. WoodSteven J. Potts, Ph.D. · 1 companies · 1 sharedSteven J. Potts, …Ting J. Xiao, C.F.A., F.R.M. · 1 companies · 1 sharedTing J. Xiao, C.F…Widya J. Mulyasasmita, Ph.D. · 1 companies · 1 sharedWidya J. Mulyasas…OncoMyx Therapeutics, Inc. · $58.0M raisedOncoMyx Therapeutics,…Ting G. XiaoTX
Ting G. Xiao Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Ting G. Xiao on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Steven J. Potts, Ph.D.11
Kanad J. Das, Ph.D.11
Ting J. Xiao, C.F.A., F.R.M.11
Benjamin J. Rovinski, Ph.D.11
Widya J. Mulyasasmita, Ph.D.11
Charles M. Baum, M.D., Ph.D.11
Leslie M. Sharp, Ph.D.11
Jason G. Rushton11
Douglas Grant McFadden, Ph.D.11
Kanad G. Das, Ph.D.11
Michael G. Wood11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.